Page 70 - பல்கலைக்கழகம் ஆஃப் ஸ்ட்ராஸ்பர்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Quelles sont les mesures sanitaires acceptables pour les Français ?
latribune.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from latribune.fr Daily Mail and Mail on Sunday newspapers.
Distinction Légion d honneur : les Alsaciennes et Alsaciens de la promotion exceptionnelle du 1er janvier
lalsace.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lalsace.fr Daily Mail and Mail on Sunday newspapers.
Coronavirus : masques, traçage quelles mesures sanitaires les Français sont-ils prêts à accepter?
lejdd.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lejdd.fr Daily Mail and Mail on Sunday newspapers.
Enzolytics, Inc. 2020 Year End Update
COLLEGE STATION, TX / ACCESSWIRE / December 30, 2020 / Enzolytics, Inc. (OTC Markets ENZC or the Company ) today shared the following update provided by Enzolytics CEO Charles Cotropia. The full content of the update is presented below. December 30, 2020
To Our Shareholders,
On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ( BCLS or BioClonetics ) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested
Enzolytics, Inc. 2020 Year End Update December 30, 2020
To Our Shareholders,
On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ( BCLS or BioClonetics ) entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested
in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple